Abstract

Our scientists have developed several MILLIPLEX^® and Single Molecule Counting (SMC™) based SARS-CoV-2-specific immunoassay kits in response to the COVID-19 research community’s growing needs for research tools used to further our understanding of the novel coronavirus. These qualitative Research Use Only (RUO) assays, which can detect antibodies against SARS-CoV-2 antigens in human serum or plasma samples, are intended to empower researchers performing vaccine efficacy, epidemiology, and population studies.  Our new MILLIPLEX^® SARS-CoV-2 panels can facilitate simultaneous detection of the SARS-CoV-2 Spike S1, Spike S2, Receptor Binding Domain (RBD), and Nucleocapsid (N) proteins and antigen-specific IgM, IgG, or IgA antibody responses on the Luminex^® multiplex platform. They are well suited for examining the immune response to the virus over the course of infection and recovery from COVID-19.  Meanwhile, our SMC™ SARS-CoV-2 kits offer the ability to characterize viral antigen specific humoral immunity with greater sensitivity, such as in cases involving acute infections and subclinical immune responses.  For these new assays, data are presented from human patient samples sets confirmed positive or negative for COVID-19 by SARS-CoV-2 PCR tests.  Overall, our new MILLIPLEX^® and SMC™ assays can assist in COVID-19 research efforts to help society overcome the current global pandemic.